SRP4981
IL-29 human
recombinant, expressed in E. coli, ≥90% (SDS-PAGE), ≥90% (HPLC)
Synonym(s):
Cytokine ZCYTO21, IFN-λ 1, IL29, Interferon-λ 1, Interleukin-29
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
biological source
human
recombinant
expressed in E. coli
assay
≥90% (HPLC), ≥90% (SDS-PAGE)
form
lyophilized
mol wt
~20 kDa
packaging
pkg of 20 μg
impurities
endotoxin, tested
NCBI accession no.
shipped in
wet ice
storage temp.
−20°C
Gene Information
human ... IL29(282618)
General description
IL-29 is distantly related to type I interferons and the IL-10 family. Expression of IL-29 is induced by viral infection which interacts with a heterodimeric class II cytokine receptor that consists of interleukin 10 receptor beta (IL10RB) and interleukin 28 receptor alpha. IL-29 exhibits common features with type I IFNs such as antiviral activity, antiproliferative activity and in vivo antitumour activity. IL-29 acts similarly to IFNs, but is less effective generally and has activity in a more limited range of cell lines. IL-29 produced in response to viral infection, activates both monocytes and macrophages producing a restricted panel of cytokines and therefore is an important factor in activating innate immune responses at the site of viral infection. IFN-λ 1 antiviral and antiproliferative activity requires Interferon-λ 2 receptor tyrosine residues. Recombinant human IL-29 produced in E. coli is a single, non-glycosylated, polypeptide chain containing 181 amino acids and having a molecular mass of 20 kDa.
Physical form
Lyophilized without additives.
Preparation Note
Centrifuge the vial prior to opening. Avoid freeze-thaw cycles.
Reconstitute in sterile dH2O not less than 100 μg/ml. This solution can then be diluted into other aqueous buffers.
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Lingxiao Xu et al.
International journal of rheumatic diseases, 18(8), 842-849 (2015-10-01)
We previously reported that interleukin-29 (IL-29) was highly expressed in the blood and synovium of rheumatoid arthritis (RA) patients and contributed to synovial inflammation by induction of proinflammatory cytokine production. Given chronic inflammation can trigger the process of bone erosion
Licia Bordi et al.
PloS one, 10(2), e0116816-e0116816 (2015-02-19)
Crimean Congo Hemorrhagic fever virus (CCHFV) is the causative agent of Crimean-Congo hemorrhagic fever, a severe disease with a mortality rate of around 30% in humans. Previous studies demonstrate that pre-treatment with type I IFNs have an antiviral effect against
Lingxiao Xu et al.
Arthritis research & therapy, 15(5), R170-R170 (2013-11-30)
We previously reported that IL-29, a newly described member of interferon (IFN) family, was overexpressed in blood and synovium of rheumatoid arthritis (RA) patients and triggered proinflammatory cytokine IL-6 and IL-8 mRNA expression in RA synovial fibroblasts (RA-FLS). This suggests